证券代码：600479 证券简称：千金药业 公告编号：2025-026 株洲千金药业股份有限公司 关于 2021 年限制性股票激励计划第二个及第三个解除限售 期解除限售条件未成就暨回购注销相关限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 株洲千金药业股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第十一届董事会第十二次会议及第十一届监事会第十一次 会议，审议通过了《关于公司 2021 年限制性股票激励计划第二个及 第三个解除限售期解除限售条件未成就暨回购注销部分限制性股票 的议案》，同意回购注销 121 名激励对象 5,490,000 股限制性股票。 经公司 2021 年第一次临时股东大会的授权, 本次回购注销事项属于 授权范围内事项，经公司董事会审议通过后实施，无需提交股东大会 审议。现将有关事项公告如下： 一、本激励计划已履行的相关程序 司 2021 年限制性股票激励计划（草案）>及其摘要》等相关议案。公 司独立董事对相关议案发表了独立意见。 2.2021 年 12 ...

证券代码：600479 证券简称：千金药业 公告编号：2025-027 株洲千金药业股份有限公司 关于 2021 年限制性股票激励计划第二个及第三个解除限售 期解除限售条件未成就暨回购注销相关限制性股票 通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、通知债权人的原因 株洲千金药业股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第十一届董事会第十二次会议及第十一届监事会第十一次 会议，审议通过了《关于公司 2021 年限制性股票激励计划第二个及 第三个解除限售期解除限售条件未成就暨回购注销相关限制性股票 的议案》。根据《上市公司股权激励管理办法》及公司《2021 年限制 性股票激励计划（草案修订稿）》《公司章程》的规定，鉴于公司 2023 年营业收入较 2020 年度增长 4.73%，未达到 2021 年限制性股票激励 计划规定的第二个解除限售期解除限售"以 2020 年度营业收入为基 数，2023 年营业收入增长率不低于 50%"的业绩考核条件、公司 2024 年营业收入较 202 ...

目 录 | 一、内部控制审计报告…………………………………………第 | 页 | | | --- | --- | --- | | 二、附件…………………………………………………………第 3—6 | 页 | | | （一）本所营业执照复印件 ………………………………………第 | 页 | 3 | | （二）本所执业证书复印件 ………………………………………第 | 页 | 4 | | （三）本所签字注册会计师执业证书复印件 …………………第 5-6 | 页 | | | 1—2 | | | 内部控制审计报告 天健审〔2025〕2-401 号 株洲千金药业股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了株洲千金药业股份有限公司（以下简称千金药业股份公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是千金 药业股份公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报 ...

2021年限制性股票激励计划 第二个及第三个解除限售期解除限售条件未成就 暨回购注销部分限制性股票的 法律意见书 湖南启元律师事务所 关于株洲千金药业股份有限公司 湖南启元律师事务所 关于株洲千金药业股份有限公司 （二）本所已严格履行了法定职责，遵循了勤勉尽责和诚实信用原则，对公 司的行为以及本次申请的合法、合规、真实、有效进行了充分的核查验证，保证 2021 年限制性股票激励计划 第二个及第三个解除限售期解除限售条件未成就 暨回购注销部分限制性股票的 法律意见书 致：株洲千金药业股份有限公司 湖南启元律师事务所（以下简称"本所"）接受株洲千金药业股份有限公司 （以下简称"公司"或"千金药业"）委托，担任千金药业 2021 年限制性股票 激励计划（以下简称"本次激励计划"）的专项法律顾问。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《国有控股上市公司（境内）实施股权激励试行办法》（国资发分配[2006]175 号）、《关于规范国有控股上市公司实施股权激励制度有关问题的通知》（国资 发分配[2008]171 ...

目 录 | 一、审计报告……………………………………………………… 第 | 1—5 页 | | --- | --- | | 二、财务报表……………………………………………………… 第 | 6—13 页 | | （一）合并资产负债表…………………………………………… | 第 6 页 | | （二）母公司资产负债表………………………………………… | 第 7 页 | | （三）合并利润表………………………………………………… | 第 8 页 | | （四）母公司利润表……………………………………………… | 第 9 页 | | （五）合并现金流量表……………………………………………第 | 10 页 | | （六）母公司现金流量表…………………………………………第 | 11 页 | | （七）合并所有者权益变动表……………………………………第 | 12 页 | | （八）母公司所有者权益变动表…………………………………第 | 13 页 | | 三、财务报表附注……………………………………………… 第 14—108 | 页 | | 四、附件……………………………………………………………第 | 109—112 页 | ...

株洲千金药业股份有限公司 2024 年度独立董事述职报告 （狄文） 本人于 2024 年 1 月 15 日，经株洲千金药业股份有限公司（以下 简称"公司"）股东会选举为公司十一届董事会独立董事，同时担任 董事会提名委员会主任委员、审计委员会委员、薪酬与考核委员会委 员职务。2024 年度，本人严格遵照《公司法》《证券法》《上市公司 独立董事管理办法》等法律法规以及《公司章程》等有关规定，重视、 勤勉履行独立董事相关专门委员会委员职责，切实维护公司及全体股 东的合法权益，现就 2024 年度工作作如下述职： 一、独立董事基本情况 狄文：男，研究生学历，医学博士，博士后。2002 年 1 月至今， 任上海交通大学医学院附属仁济医院妇产科主任医师、教授；2001 年 9 月至 2011 年 7 月和 2015 年 1 月至 2021 年 2 月，任上海交通大 学医学院附属仁济医院妇产科主任；2011 年 8 月至 2021 年 2 月，任 上海交通大学医学院附属仁济医院副院长；2023 年 2 月至今，任中 国医师协会妇产科医师分会会长。 本人作为公司独立董事，本人及直系亲属、主要社会关系均未在 公司担任除独立董事 ...

本人作为株洲千金药业股份有限公司（以下简称"公司"）的独 立董事，本人严格按照《公司法》《上市公司独立董事管理办法》《公 司章程》等相关法律、法规、规范性文件的规定，在 2024 年的工作 中，勤勉、尽责、忠实履行职责，按时出席相关会议，发挥本人在会 计、审计等方面的专业优势，认真审议各项议案，切实维护全体股东 尤其是广大中小股东的合法权益。现将本人在 2024 年度履行独立董 事职责的情况报告如下： 一、独立董事基本情况 （一）个人工作履历 株洲千金药业股份有限公司 2024 年度独立董事述职报告 （周季平） 周季平：男，1965 年生，本科学历。现任湖南省注册会计师资 产评估行业党委副书记、湖南建业会计师事务所（特殊普通合伙）合 伙人、中共湖南建业联合支部委员会书记。担任的社会职务有：中国 注册会计师协会第五届理事会理事，湖南省注册会计师协会第四届理 事会副会长，湖南省房地产协会中介委员会副主任委员，湖南省土地 估价师与土地登记代理人协会副会长，湖南省第十一届政协委员。 （二）是否存在独立性情况的说明 本人作为公司的独立董事，任职符合《上市公司独立董事管理办 法》第六条规定的独立性要求，亦不存在影响独立性 ...

株洲千金药业股份有限公司 2024 年度独立董事述职报告 （马理） 本人作为株洲千金药业股份有限公司（以下简称"公司"）的独 立董事，在任职期间严格按照《公司法》《证券法》《上市公司治理 准则》《上市公司独立董事管理办法》等法律法规、规范性文件的有 关规定，诚信、勤勉、忠实地履行职责，认真审议董事会各项议案， 对重大事项发表独立意见，积极维护公司整体利益和全体股东尤其是 中小股东的合法权益。本人现就 2024 年度履职情况述职如下： 一、基本情况 （一）工作履历、专业背景及兼职情况 马理：男，博士。2004 年 7 月至 2006 年 7 月，在武汉大学理论 经济学博士后流动站从事博士后研究工作；2006 年 8 月至 2020 年 10 月，在武汉大学经济与管理学院工作，任副教授、教授、博士生导师 （期间，2009 年 9 月至 2010 年 9 月，在美国加州大学圣地亚哥分校， 任访问学者；2015 年 9 月至 2016 年 3 月在德国奥尔登堡大学，任客 座教授）；2020 年 10 月至今，任湖南大学金融与统计学院教授、博 士生导师、湖南省芙蓉学者奖励计划特聘教授、湖南大学岳麓学者。 2023 年 ...

Financial Performance - The company's consolidated net profit attributable to shareholders for the year ended December 31, 2024, was CNY 230,756,619.25, representing a decrease of 27.98% compared to the previous year[6]. - The total operating revenue for 2024 was CNY 3,629,804,492.14, reflecting a decline of 4.44% from the previous year[24]. - The net cash flow from operating activities decreased by 10.01% to CNY 398,766,454.60 compared to the previous year[24]. - The total assets as of the end of 2024 were CNY 4,556,298,077.73, a decrease of 2.58% from the end of 2023[24]. - The net assets attributable to shareholders increased by 3.04% to CNY 2,462,279,280.80 compared to the end of 2023[24]. - Basic earnings per share decreased by 26.43% to CNY 0.5579 compared to CNY 0.7583 in the previous year[25]. - Net profit attributable to shareholders decreased by 27.98% year-on-year, with adjustments reflecting an increase of CNY 2.7333 million in the current period[25]. - The weighted average return on equity fell to 9.54%, down from 13.91% in the previous year, a decrease of 4.37 percentage points[25]. - The total profit achieved was CNY 33,530.76 million, down 27.17% year-on-year[52]. - The net profit attributable to shareholders was CNY 23,075.66 million, reflecting a decline of 27.98% compared to the previous year[52]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of CNY 3.6 per 10 shares (including tax) based on the number of shares on the dividend record date[6]. - The company reported a cumulative undistributed profit of CNY 1,229,469,847.51 as of December 31, 2024[6]. - The cumulative cash dividend over the last three accounting years reached 556,610,752.10 RMB, with a cash dividend ratio of 180.53% based on the average annual net profit of 308,326,012.52 RMB[163]. Research and Development - R&D investment reached 235 million yuan, a year-on-year increase of 61.70%, with 56 new R&D projects initiated and a total of 119 projects under development[38]. - Research and development expenses increased by 47.72% to CNY 220,204.53 million, indicating a strategic focus on innovation[54]. - The total R&D investment for 2024 is CNY 234.54 million, accounting for 6.46% of total revenue and 12.15% of industrial revenue[69]. - The company is focusing on the development of innovative drugs in the fields of oncology and sleep medicine, aiming to create new growth points[120]. - The company has received approval for two projects: Compound Acetaminophen and Dapoxetine Hydrochloride tablets, while several other projects are in various stages of clinical research and registration[90][91]. Market and Product Development - The company launched 5 new products during the year, including Yimucao Granules and Qingbai Wash Liquid[34]. - The market share of the company's gynecological product, Qianjin Capsule, reached 25.8%, while the sales scale of Bu Xue Yi Mu Granules exceeded 180 million yuan, with a market share of 10.81%[36]. - The company is focusing on expanding its product line in women's health, with unique products like Gynecology Qianjin tablets and Blood Supplement Yimother pills[87]. - The company is actively pursuing international registration for its products, indicating a strategy for market expansion[88]. Operational Efficiency - The average inventory amount decreased by 25% year-on-year, and the average inventory turnover days reduced by 4 days[40]. - The production efficiency improvements resulted in a 12% increase in the output of dosage forms, reaching 3 billion tablets[40]. - The company has established a new organizational structure with 6 primary flexible teams and recruited 92 high-potential talents during the reporting period[36]. - The company has implemented a digital transformation strategy to reduce costs and improve efficiency across its operations[118]. Environmental and Social Responsibility - The company has invested 605.8 million RMB in environmental protection during the reporting period[169]. - The company has implemented a waste gas collection and treatment system at the raw material drug workshop, with online detection systems installed[178]. - Total investment in social responsibility projects amounted to CNY 2.7859 million, benefiting over 24.57 million people through the "Hello Qianjin" public welfare project[179]. - The "Hello Qianjin - Women's Health China Tour" project has reached over 60 million women since its launch in 2016, with activities conducted in over 1,600 schools and 200 companies[180]. Governance and Management - The company has established a transparent performance evaluation and incentive mechanism for senior management, linking their compensation to the company's operational performance[127]. - The company has a total of 5,270 employees, with 1,833 in the parent company and 3,437 in major subsidiaries[152]. - The company has undergone a board restructuring with several new appointments, including the election of Chen Jun and Di Wen as directors[140]. - The company has a new compensation plan for senior management for the years 2024 to 2026[138]. Future Outlook - The company aims to achieve a turnaround by Q2 2025, with specific performance targets set[132]. - The company plans to increase R&D investment to at least 10% of industrial sales, enhancing collaboration with external partners and expanding its R&D team[118]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 200 million yuan earmarked for potential deals[133]. - The company has provided a positive outlook for the next quarter, projecting a revenue growth of 10% to 1.32 billion yuan[134].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,005,023,395.38, representing a year-on-year increase of 0.43% compared to CNY 1,000,740,881.98 in the same period last year[4] - Net profit attributable to shareholders increased by 15.06% to CNY 53,155,316.53 from CNY 46,198,047.86 year-on-year[4] - The basic earnings per share rose by 16.43% to CNY 0.1254, up from CNY 0.1077 in the previous year[5] - Net profit for Q1 2025 was ¥72,319,004.16, up from ¥61,007,849.98 in Q1 2024, reflecting a growth of 18.6%[20] - The net profit attributable to shareholders of the parent company for Q1 2025 was ¥53,155,316.53, compared to ¥46,198,047.86 in Q1 2024, an increase of 15.5%[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.1254, up from ¥0.1077 in Q1 2024, marking a rise of 16.0%[20] - The company reported a total comprehensive income of ¥72,319,004.16 for Q1 2025, compared to ¥61,007,602.99 in Q1 2024, an increase of 18.6%[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,661,288,930.48, reflecting a 2.30% increase from CNY 4,556,298,077.73 at the end of the previous year[5] - The company's total current assets decreased from 2,728,924,172.75 RMB as of December 31, 2024, to 2,539,178,640.44 RMB as of March 31, 2025, a decline of approximately 6.9%[14] - Total current liabilities increased from 1,332,793,102.67 RMB to 1,365,133,748.56 RMB, an increase of approximately 2.4%[15] - Total liabilities as of the reporting date were ¥1,447,823,368.47, compared to ¥1,417,151,519.88 in the previous period, an increase of 2.2%[18] - Total equity attributable to shareholders of the parent company was ¥2,517,440,737.20, up from ¥2,462,279,280.07, reflecting a growth of 2.24%[18] Cash Flow - The net cash flow from operating activities improved by 26.93%, with a net outflow of CNY 124,368,913.13 compared to CNY 170,209,301.10 in the same period last year[4] - Operating cash inflow totaled $892.80 million, an increase from $883.31 million year-over-year[22] - Operating cash outflow amounted to $1,017.17 million, down from $1,053.51 million year-over-year[22] - Net cash flow from operating activities was -$124.37 million, an improvement from -$170.21 million year-over-year[22] - The ending cash and cash equivalents balance was $921.32 million, down from $1,730.24 million year-over-year[23] - The company reported a decrease in cash and cash equivalents due to negative cash flow from operating and investing activities[23] Receivables and Expenses - Accounts receivable increased by 51.46%, primarily due to changes in the company's credit policy[8] - Other receivables surged by 494.03%, mainly due to an increase in advance payments and guarantees[8] - Financial expenses rose by 126.22%, attributed to a decrease in bank deposit income[8] - Research and development expenses for Q1 2025 totaled ¥61,461,708.51, slightly higher than ¥60,460,413.73 in Q1 2024, an increase of 1.66%[19] - The company reported a significant increase in other receivables from 15,745,373.69 RMB to 93,532,170.01 RMB, an increase of about 493.5%[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 42,636[10] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group Co., Ltd., holds 119,381,136 shares, accounting for 28.1% of total shares[10] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect future financial reporting[23] - The management team remains focused on improving operational efficiency and cash flow management strategies moving forward[22]